Berenberg raised the firm’s price target on Merck to $143 from $140 and keeps a Buy rating on the shares. The firm increased its Winrevair peak sales forecast to $6.8B from $4.8B following its “broad” U.S. approval in pulmonary arterial hypertension and higher than expected price. The label allows for convenient, at-home administration without onerous safety monitoring, the analyst tells investors in a research note. The firm believes Merck is well positioned to deliver above sector average sales growth and margin expansion in the medium term.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Piper Sandler pharmaceuticals analysts hold an analyst/industry conference call
- Merck initiates Phase 3 clinical trial of MK-1084
- Daiichi Sankyo, Merck announe first patient dosed in REJOICE-Ovarian01 trial
- Merck price target raised to $142 from $139 at Truist
- PDS Biotechnology price target lowered to $5 from $16 at Alliance Global Partners